- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...

- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of ...

Raritan-based Ortho Clinical Diagnostics said April 3, it is launching to market its COVID-19 antibody test. The VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack testing kits are ...

RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for ...

-- Ortho's new VITROS ® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior ...

Vaccination rates may be steadily climbing across the country, but companies hope COVID-19 testing won't slow down any time soon. In fact, manufacturers are now ramping up production of antigen and ...

– The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months “Ortho’s ...

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today introduced and announced the U.S. Food and ...

— Ortho’s new VITROS (R) Anti-SARS-CoV-2 Total N test detects the individual’s immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or ...